The Manufacturers Life Insurance Company Makes New $145.66 Million Investment in BridgeBio Pharma, Inc. $BBIO

Posted by Geri Gentry on Aug 25th, 2026

The Manufacturers Life Insurance Company bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,955,733 shares of the company’s stock, valued at approximately $145,663,000.

Several other large investors have also recently modified their holdings of BBIO. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma during the first quarter worth $35,000. First Trust Advisors LP increased its holdings in BridgeBio Pharma by 200.4% in the second quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock valued at $11,386,000 after purchasing an additional 175,918 shares during the period. Baird Financial Group Inc. increased its holdings in BridgeBio Pharma by 1.8% in the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock valued at $1,816,000 after purchasing an additional 731 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in BridgeBio Pharma during the 2nd quarter worth $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in BridgeBio Pharma by 2.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock worth $4,132,000 after purchasing an additional 2,206 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

BBIO has been the topic of several recent research reports. Morgan Stanley reduced their price target on BridgeBio Pharma from $98.00 to $97.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Raymond James Financial downgraded BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Piper Sandler lifted their price objective on BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Mizuho cut their price objective on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 16th. Finally, Truist Financial upped their target price on BridgeBio Pharma from $102.00 to $107.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average target price of $100.79.

Check Out Our Latest Research Report on BridgeBio Pharma

Insiders Place Their Bets

In other news, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $67.46, for a total value of $2,698,400.00. Following the transaction, the chief executive officer directly owned 535,686 shares of the company’s stock, valued at $36,137,377.56. The trade was a 6.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total value of $1,442,028.00. Following the sale, the director owned 22,579 shares in the company, valued at approximately $1,896,636. The trade was a 43.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 387,343 shares of company stock valued at $30,289,400 over the last 90 days. 14.23% of the stock is owned by company insiders.

BridgeBio Pharma Stock Down 0.5%

BBIO stock opened at $81.07 on Tuesday. The firm has a market cap of $15.85 billion, a price-to-earnings ratio of -22.71 and a beta of 0.96. BridgeBio Pharma, Inc. has a 12-month low of $46.81 and a 12-month high of $93.42. The company’s fifty day simple moving average is $79.11 and its 200 day simple moving average is $73.31.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The business had revenue of $243.68 million for the quarter, compared to analyst estimates of $220.91 million. During the same quarter in the prior year, the business earned ($0.95) earnings per share. The company’s revenue was up 120.4% on a year-over-year basis. Research analysts expect that BridgeBio Pharma, Inc. will post -2.62 earnings per share for the current year.

BridgeBio Pharma Company Profile

(Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.